Mechanisms underlying phasic contractions of pregnant rat myometrium stimulated with aluminum fluoride.
OBJECTIVE
The mechanisms underlying phasic myometrial contractions are unknown at this time. Phasic contractions, however, are characterized by repetitive cycles of elevated intracellular calcium (i.e., calcium oscillations). These studies were performed to test the hypothesis that mechanisms underlying phasic myometrial contractions are similar to those producing classic cytosolic calcium oscillations.


METHODS
Uterine tissue was obtained from pregnant Sprague-Dawley rats (i.e., day 18 to 22 of gestation). In vitro isometric contraction studies were performed with longitudinal strips of myometrial tissue; computer-digitized data were analyzed for contraction area and normalized for tissue cross-section area. Dose-response studies were performed with aluminum fluoride and various inhibitors of cytosolic calcium oscillations.


RESULTS
Aluminum fluoride stimulated a significant increase in phasic contractions. In contrast, the addition of 2-nitro-4-carboxyphenyl-N,N-diphenylcarbamate (an inhibitor of phosphoinositide-specific phospholipase C), adenine (an inhibitor of calcium-induced calcium release), and phorbol 12,13-dibutyrate (an activator of protein kinase C) resulted in significant suppression of aluminum fluoride-stimulated contractions. Similarly, nifedipine (an L-type calcium channel blocker) and removal of extracellular calcium significantly inhibited phasic myometrial contractions.


CONCLUSIONS
These studies have confirmed that phosphoinositide-specific phospholipase C, calcium-induced calcium release, protein kinase C, and transmembrane calcium influx are important components of the intracellular calcium oscillator that generates agonist-stimulated phasic contractions of pregnant myometrial tissue.
Phillippe
M
M
Department of Obstetrics and Gynecology, University of Chicago, IL.
D017607:Aluminum Compounds / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000818:Animals; D002118:Calcium / Q000378:metabolism; D005260:Female; D005459:Fluorides / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D009215:Myometrium / Q000187:drug effects* / Q000502:physiology; D010716:Phosphatidylinositols / Q000378:metabolism; D011247:Pregnancy; D011493:Protein Kinase C / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D010738:Type C Phospholipases / Q000502:physiology; D014590:Uterine Contraction / Q000187:drug effects*
D017607:Aluminum Compounds; D010716:Phosphatidylinositols; D011493:Protein Kinase C; D010738:Type C Phospholipases; D005459:Fluorides; D002118:Calcium; C032311:aluminum fluoride